According to filings with the U.S. Securities and Exchange Commission, Affinity Biosensors is raising up to $4,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Kenneth Babcock played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Affinity Biosensors
LifeScale AST System: Rapid Antimicrobial Susceptibility Testing Same-day reporting from positive blood cultures RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING POPULATION PROFILING DELAYED-GROWTH PHENOTYPES RAPID and PRECISE COUNTS and MASS MEASUREMENT OF INDIVIDUAL MICROBES LOW SAMPLE VOLUME AND CONCENTRATIONS Affinity Biosensors has developed the LifeScale AST system which utilizes mass sensing technology to produce a phenotypic AST result for Gram-negative bacteria directly from a positive blood culture bottle in 4.5 hours. The Companys patented microfluidic sensor measures the mass of individual microbes at the femtogram level. The touchscreen-driven workflow requires minimal hands-on time by the technologist. MIC results are reported as well as SIR interpretive results using CLSI or FDA break-points. Multiple samples can be processed on this bench-top instrument. Reagent kits contain all consumables needed to run one sample and are stable at room temperature. The Gram-negative panel is comprised of 14 antibiotics in a 96-well plate format.

To learn more about Affinity Biosensors, visit http://affinitybio.com/
Company Linkedin Page: https://www.linkedin.com/company/affinity-biosensors/

Contact:
Kenneth Babcock, Chief Executive Officer
805-960-5100
https://www.linkedin.com/in/ken-babcock-695ab412/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.